The Nobel Committee at the Karolinska Institute of Stockholm has done it again. They have rewarded one of those investigations that, for years, seemed like a mere footnote in textbooks but are now the backbone of revolutionary treatments. The Nobel Prize for Physiology and Medicine of 2025 has been jointly awarded to Japanese scientist Shimon Sakaguchi and Americans Mary E. Brunkow and Fred Ramsdell for their groundbreaking work on Regulatory T cells and the pivotal role of the Foxp3 gene in immune function.
The Beginning. In the previous decade, Sakaguchi identified a unique subset of T lymphocytes that did not attack the body’s own cells but instead suppressed the activity of other T cells. He characterized these cells, now known as regulatory T cells (TREGS) , in a seminal 1995 publication . This finding was transformative ; it demonstrated that without TREGS, the immune system could become hyperactive and start attacking the body’s tissues, leading to life-threatening autoimmune diseases. Sakaguchi had effectively uncovered the natural mechanism the body employs to maintain immune tolerance and prevent self-destruction. However, a crucial piece remained elusive: what determines whether a T cell becomes a peacemaker or a soldier?
Brunkow and Ramsdell. Although Sakaguchi’s discovery was revolutionary, skepticism remained prevalent in the scientific community. The pivotal answer emerged in 2001, far from the 2025 award date. Researchers led by Mary E. Brunkow were probing a rare and deadly autoimmune disease in children called IPEX syndrome and identified a critical gene: Foxp3 . Meanwhile, Fred Ramsdell ’s team was investigating a mouse model exhibiting analogous symptoms and reached the same conclusion: the faulty gene was indeed Foxp3 .
The Connection. The link formed was immediate and explosive: Foxp3 serves as the “master switch”. When activated in a T lymphocyte, it instructs the cell to become a TREG. Without functional Foxp3, regulatory T cells do not exist, leading to chaos in the immune system. Sakaguchi’s discovery finally had a genetic basis, lending credibility to the foundational work he had laid out.
A Revolution. This dual discovery — Sakaguchi’s cellular finding and Brunkow and Ramsdell’s genetic elucidation — has reshaped the paradigms of immunology and unlocked two promising therapeutic avenues.
On one hand, this groundbreaking research opens the door to combat autoimmune diseases . With insufficient TREGS, the body essentially turns on itself. The solution lies in boosting these regulatory cells; various clinical trials have begun that involve extracting patient T cells, manipulating them in the lab, and reinfusing them into the patient. This approach is known as immunotherapy .
Simultaneously, this work is pivotal in the fight against cancer . Tumors have been shown to employ TREGS as a shield against the immune system’s attacks. These pacifying cells obstruct “soldier” T lymphocytes from targeting cancerous cells. New immunotherapies aim to temporarily incapacitate these TREGS or inhibit Foxp3’s action in tumor microenvironments, allowing the immune system to efficiently eradicate cancer cells. Such approaches have shown particular promise in the treatment of tumors like lymphoma.
Time Has Passed. It is intriguing to note the lengthy duration between the initial discoveries and their formal recognition with a Nobel Prize. The long wait can be attributed to the necessity of establishing the clinical relevance of these findings, especially given their potential for addressing severe healthcare challenges.